Prior and Concomitant Therapy Sample Clauses

Prior and Concomitant Therapy. During the study, participants are not allowed to be treated with the following treatments in addition to the study drug: • Antiperistaltic drugs, e.g. loperamide, • Antibiotics • Antipyretics • Intestinal antiseptics, e.g. 8-hydroxyquinoline • Respiratory decongestants, e.g phenylephrine • Antitussive medication, e.g noscapin • Absorbents, e. g. diosmectite, charcoal, pectin, psyllium • Zinc-containing medication • Homemade ORS • ACE Inhibitors • Antispasmodics • Drugs for symptomatic treatment of diarrhea, e.g. pancreatic enzymes, anticholinergic drugs, opiates, diphenoxylate. Subjects on continuous probiotic treatment (e.g. Lactobacillus, Bifidobacterium, yeast) or probiotic- containing supplements/formula of the same product/brand for at least 4 weeks prior to study start can be included. The presence of bloody or purulent stool and fever may indicate either the presence of invasive bacteria as a reason for diarrhea or the presence of another severe disease, warranting causal (e.g. antibiotic) treatment or further investigation. In addition, Racecadotril has not been investigated in patients with antibiotic-associated diarrhea. Therefore, Racecadotril should not be administered under these conditions. Subjects who need treatment with the above listed medication should be withdrawn from the study. Dietary modifications for thickening of the stools are allowed. Any intake of other medication is allowed as judged appropriate by the Investigator except those on the list of prohibited medications above. All medication taken by the subject during the study (from signing the informed consent form through post-study follow-up) is to be recorded on the Concomitant Medication form, except for study drug.